Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia

原文：2021年发布于 Curr Urol Rep 22卷第1期 5  浏览量：1002次 原文链接

作者单位： Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA. Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA. steven.kaplan@mountsinai.org.

归属分类：良性前列腺增生治疗及预后证据

DOI： 10.1007/s11934-020-01017-7

关键词： Acetanilides Adrenergic beta-3 Receptor Agonists Aged Humans Lower Urinary Tract Symptoms Male Prostatic Hyperplasia/complications/*drug therapy Randomized Controlled Trials as Topic Thiazoles Treatment Outcome Urinary Bladder Overactive/complications/*drug therapy Urological Agents Lower urinary tract symptoms Mirabegron Overactive Prostatic hyperplasia Urinary bladder

文献简介

PURPOSE OF REVIEW: To review the efficacy and safety of mirabegron in men with overactive bladder (OAB) and benign prostatic hyperplasia (BPH). RECENT FINDINGS: Numerous studies have shown mirabegron to be efficacious and safe in treating symptoms of OAB. More recent studies evaluating the use of mirabegron in men with OAB and BPH have also shown the medication to be effective with few adverse side effects when used as monotherapy or in combination therapy. Mirabegron is an effective and safe treatment for men with OAB and BPH.

原文网址：https://pubmed.ncbi.nlm.nih.gov/33411109/

The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis

Endoscopic enucleation of the prostate (EEP). The same but different-a systematic review

热门文献